Jordan M Winter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4885427/publications.pdf

Version: 2024-02-01

57758 27406 11,709 139 44 106 citations h-index g-index papers 139 139 139 14983 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Racial disparities in operative management of localized, non-functional pancreatic neuroendocrine tumors in surgically fit patients. Hpb, 2022, 24, 217-225.	0.3	3
2	Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. American Journal of Surgery, 2022, 223, 927-932.	1.8	4
3	Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. Hpb, 2022, 24, 925-932.	0.3	1
4	A Propensity-Matched Analysis of the Postoperative Venous Thromboembolism Rate After Pancreatoduodenectomy Based on Operative Approach. Journal of Gastrointestinal Surgery, 2022, 26, 623-634.	1.7	5
5	A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Surgery, 2022, 172, 257-264.	1.9	9
6	Clinical development of IDH1 inhibitors for cancer therapy. Cancer Treatment Reviews, 2022, 103, 102334.	7.7	18
7	Weight Tracking as a Novel Prognostic Marker After Pancreatectomy. Annals of Surgical Oncology, 2022, 29, 3450-3459.	1.5	6
8	ASO Author Reflection: Post-pancreatectomy Weight Trends Predict Recurrence and Survival. Annals of Surgical Oncology, 2022, , 1.	1.5	1
9	Black race is independently associated with underutilization of preoperative chemotherapy in clinical stage T2 or higher gastric adenocarcinoma. Surgery, 2022, 171, 1562-1569.	1.9	1
10	Intraoperative Cytologic Sampling for Resected Pancreatic and Periampullary Adenocarcinoma with Implications for Locoregional Recurrence-Free Survival. Journal of the American College of Surgeons, 2022, 234, 48-53.	0.5	1
11	ASO Visual Abstract: Weight Tracking as a Novel Prognostic Marker After Pancreatectomy. Annals of Surgical Oncology, 2022, 29, 3462-3462.	1.5	2
12	Medicaid expansion is associated with a higher likelihood of early diagnosis, resection, transplantation, and overall survival in patients with hepatocellular carcinoma. Hpb, 2022, 24, 1482-1491.	0.3	11
13	Liver Endothelium Promotes HER3-Mediated Cell Survival in Colorectal Cancer with Wild-Type and Mutant <i>KRAS</i> . Molecular Cancer Research, 2022, 20, 996-1008.	3.4	6
14	Time to Neoadjuvant Chemotherapy Initiation is not Associated With Survival in Pancreatic Cancer. Journal of Surgical Research, 2022, 276, 369-378.	1.6	2
15	Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancer. Psycho-Oncology, 2022, 31, 1390-1398.	2.3	20
16	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular Biology, 2022, 44, 2015-2028.	2.4	5
17	Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules, 2022, 12, 815.	4.0	15
18	Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors. Nature Cancer, 2022, 3, 852-865.	13.2	37

#	Article	IF	CITATIONS
19	Association Between Operative Approach and Venous Thromboembolism Rate Following Hepatectomy: a Propensity-Matched Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 2778-2787.	1.7	7
20	Is the Use of Intraoperative Frozen Section During Pancreaticoduodenectomy Justified?. Journal of Gastrointestinal Surgery, 2021, 25, 728-736.	1.7	5
21	Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. American Journal of Surgery, 2021, 221, 500-504.	1.8	7
22	Reassessing the role of surgery in the elderly or chronically sick with proximal extrahepatic cholangiocarcinoma. Surgery, 2021, 169, 233-239.	1.9	5
23	Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). Annals of Surgical Oncology, 2021, 28, 1060-1068.	1.5	1
24	A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database. Journal of Surgical Oncology, 2021, 123, 949-956.	1.7	22
25	Mortality and Survival Among Octogenarians with Localized Pancreatic Head Cancer: a National Cancer Database Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 2582-2592.	1.7	8
26	ASO Author Reflections: Prediagnosis Weight Loss: Early Detection and Postoperative Prognosis Among Patients with Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 6293-6293.	1.5	1
27	Weight Loss as an Untapped Early Detection Marker in Pancreatic and Periampullary Cancer. Annals of Surgical Oncology, 2021, 28, 6283-6292.	1.5	28
28	Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Journal of Pancreatic Cancer, 2021, 7, 31-38.	0.9	2
29	Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. European Journal of Cancer, 2021, 147, 17-28.	2.8	14
30	Pancreatic Cancer–Associated Diabetes is Clinically Distinguishable From Conventional Diabetes. Journal of Surgical Research, 2021, 261, 215-225.	1.6	7
31	The importance of multimodal therapy in the management ofÂnonmetastatic adenosquamous carcinoma of the pancreas: AnalysisÂof treatment sequence and strategy. Surgery, 2021, 169, 1102-1109.	1.9	7
32	Sentinel lymph node biopsy guideline concordance in melanoma: Analysis of the National Cancer Database. Journal of Surgical Oncology, 2021, 124, 669-678.	1.7	12
33	Unintentional Weight Loss as a Marker of Malignancy Across Body Weight Categories. Current Cardiovascular Risk Reports, 2021, 15, 1.	2.0	0
34	The importance of timeâ€toâ€adjuvant treatment on survival with pancreatic cancer: A systematic review and metaâ€analysis. Cancer Reports, 2021, 4, e1390.	1.4	4
35	Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy. Surgery, 2021, 170, 207-214.	1.9	19
36	Facility type and size-stratified analysis of management patterns and outcomes of patients with localized non-functional pancreatic neuroendocrine tumors. Hpb, 2021, , .	0.3	1

#	Article	lF	Citations
37	Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era. American Surgeon, 2021, 87, 1386-1395.	0.8	3
38	Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma. Hpb, 2021, , .	0.3	2
39	Defining Common Features in High Impact and Highly Cited Journal Articles on Pancreatic Tumors. Annals of Surgery, 2021, 274, 977-984.	4.2	2
40	Optimizing cancer cure dialog: an analysis of pancreatic cancer patients' views regarding survival and cure. Supportive Care in Cancer, 2020, 28, 3731-3737.	2.2	1
41	Cancer, Cardiovascular Disease, and Body Weight: a Complex Relationship. Current Cardiovascular Risk Reports, 2020, 14, 1.	2.0	0
42	Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts. Frontiers in Oncology, 2020, 10, 586727.	2.8	14
43	Neoadjuvant chemotherapy is associated with improved survival in patients with leftâ€sided pancreatic adenocarcinoma. Journal of Surgical Oncology, 2020, 122, 1595-1603.	1.7	7
44	A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surgical Oncology, 2020, 33, 118-125.	1.6	4
45	Patient-centered Weight Tracking as an Early Cancer Detection Strategy. Journal of Cancer Prevention, 2020, 25, 181-188.	2.0	5
46	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. Oncotarget, 2020, 11, 3489-3501.	1.8	30
47	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Research, 2019, 79, 4491-4502.	0.9	27
48	Enhancing Patient Outcomes while Containing Costs after Complex Abdominal Operation: A Randomized Controlled Trial of the Whipple Accelerated Recovery Pathway. Journal of the American College of Surgeons, 2019, 228, 415-424.	0.5	38
49	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Molecular Cancer Research, 2019, 17, 1815-1827.	3.4	40
50	Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential. Journal of the American College of Surgeons, 2019, 228, 721-729.	0.5	35
51	Host <i>IDO2</i> Gene Status Influences Tumor Progression and Radiotherapy Response in <i>KRAS</i> -Driven Sporadic Pancreatic Cancers. Clinical Cancer Research, 2019, 25, 724-734.	7.0	48
52	RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Molecular Cancer Research, 2019, 17, 508-520.	3.4	17
53	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons, 2018, 226, 596-603.	0.5	5
54	Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biology and Therapy, 2018, 19, 249-253.	3.4	18

#	Article	IF	Citations
55	Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 288-294.	1.7	6
56	Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer. Annals of Surgery, 2018, 267, 364-369.	4.2	26
57	Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry. Journal of Pancreatic Cancer, 2018, 4, 17-24.	0.9	0
58	Metabolic Dependencies in Pancreatic Cancer. Frontiers in Oncology, 2018, 8, 617.	2.8	60
59	Surgeon-Led Imaging Review for Patients with Periampullary Disease: An Important Aspect of the Preoperative Consultation. Journal of Pancreatic Cancer, 2018, 4, 52-59.	0.9	0
60	Pancreatic Cancer–Associated Depression. Pancreas, 2018, 47, 1065-1077.	1.1	30
61	Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 4004-4011.	1.5	21
62	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
63	The Combination of Pancreas Texture and Postoperative Serum Amylase in Predicting Pancreatic Fistula Risk. American Surgeon, 2018, 84, 889-896.	0.8	5
64	CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Molecular Cancer Research, 2017, 15, 696-707.	3.4	39
65	Posttranscriptional Regulation of <i>PARG</i> mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Research, 2017, 77, 5011-5025.	0.9	59
66	A Prospective Randomized Multicenter Trial of Distal Pancreatectomy With and Without Routine Intraperitoneal Drainage. Annals of Surgery, 2017, 266, 421-431.	4.2	111
67	Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Research, 2017, 77, 4460-4471.	0.9	87
68	Total parenteral nutrition in patients following pancreaticoduodenectomy: lessons from 1184 patients. Journal of Surgical Research, 2017, 218, 156-161.	1.6	14
69	Increasing resident utilization and recognition of the critical view of safety during laparoscopic cholecystectomy: a pilot study from an academic medical center. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 1627-1635.	2.4	35
70	Intraoperative Frozen Section Analysis of the Pancreas: A Case Report and Review of the Literature. Case Reports in Pancreatic Cancer, 2016, 2, 71-74.	0.1	1
71	The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. International Journal of Biological Sciences, 2016, 12, 273-282.	6.4	89
72	Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (â‰20-mm Invasive Component). Annals of Surgery, 2016, 263, 793-801.	4.2	60

#	Article	IF	CITATIONS
73	HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Molecular Cancer Research, 2016, 14, 599-611.	3.4	45
74	Adenosquamous Carcinoma of the Pancreas in a Patient with BRCA2 Mutation: A Case Report. Case Reports in Pancreatic Cancer, 2015, 1, 22-25.	0.1	2
75	Diagnostic Evaluation and Staging of Pancreatic Ductal Adenocarcinoma. Seminars in Oncology, 2015, 42, 19-27.	2.2	45
76	The Value of Drains as a Fistula Mitigation Strategy for Pancreatoduodenectomy: Something for Everyone? Results of a Randomized Prospective Multi-institutional Study. Journal of Gastrointestinal Surgery, 2015, 19, 21-31.	1.7	83
77	A Prospective, Randomized, Double-Blind, Placebo Controlled Trial on the Efficacy of Ethanol Celiac Plexus Neurolysis in Patients with Operable Pancreatic and Periampullary Adenocarcinoma. Journal of the American College of Surgeons, 2015, 220, 497-508.	0.5	26
78	Delayed Gastric Emptying After Pancreaticoduodenectomy: an Analysis of Risk Factors and Cost. Journal of Gastrointestinal Surgery, 2015, 19, 1572-1580.	1.7	75
79	Segment and Fit Thresholding: A New Method for Image Analysis Applied to Microarray and Immunofluorescence Data. Analytical Chemistry, 2015, 87, 9715-9721.	6.5	20
80	Incidence and Severity of Pancreatogenic Diabetes After Pancreatic Resection. Journal of Gastrointestinal Surgery, 2015, 19, 217-225.	1.7	92
81	MUC1 Promoter–Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	3.4	18
82	Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget, 2015, 6, 27312-27331.	1.8	47
83	dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biology and Therapy, 2014, 15, 688-698.	3.4	39
84	A Randomized Prospective Multicenter Trial of Pancreaticoduodenectomy With and Without Routine Intraperitoneal Drainage. Annals of Surgery, 2014, 259, 605-612.	4.2	324
85	The HYSLAR Trial. Annals of Surgery, 2014, 260, 445-455.	4.2	61
86	PARP Inhibitors for Chemopreventionâ€"Letter. Cancer Prevention Research, 2014, 7, 1170-1171.	1.5	5
87	Non-neoplastic Epithelial Cysts of the Pancreas: A Rare, Benign Entity. Journal of Gastrointestinal Surgery, 2014, 18, 523-531.	1.7	31
88	Intraoperative Pancreatoscopy: A Valuable Tool for Pancreatic Surgeons?. Journal of Gastrointestinal Surgery, 2014, 18, 1100-1107.	1.7	21
89	Does Resident Experience Affect Outcomes in Complex Abdominal Surgery? Pancreaticoduodenectomy as an Example. Journal of Gastrointestinal Surgery, 2014, 18, 279-285.	1.7	37
90	HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Research, 2014, 74, 1128-1140.	0.9	91

#	Article	IF	CITATIONS
91	988 Sequence Alterations in the Wee1 Non-Coding Region Is a Facilitator and Marker for Pancreatic Tumorigenesis. Gastrointestinal Endoscopy, 2014, 79, AB188.	1.0	O
92	A case of periampullary adenocarcinoma in neurofibromatosis type 1. Journal of Gastrointestinal Oncology, 2014, 5, E96-9.	1.4	2
93	Splenic Vein Thrombosis Is Associated with an Increase in Pancreas-Specific Complications and Reduced Survival in Patients Undergoing Distal Pancreatectomy for Pancreatic Exocrine Cancer. Journal of Gastrointestinal Surgery, 2013, 17, 1392-1398.	1.7	17
94	Acinar Cell Cystadenoma of the Pancreas: Report of Three Cases and Literature Review. Journal of Gastrointestinal Surgery, 2013, 17, 1322-1326.	1.7	11
95	Preoperative Imaging for Resectable Periampullary Cancer: Clinicopathologic Implications of Reported Radiographic Findings. Journal of Gastrointestinal Surgery, 2013, 17, 1098-1106.	1.7	27
96	Up and down or side to side? A systematic review and meta-analysis examining the impact of incision on outcomes after abdominal surgery. American Journal of Surgery, 2013, 206, 400-409.	1.8	73
97	Defining Treatment and Outcomes of Hepaticojejunostomy Failure Following Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2013, 17, 451-460.	1.7	67
98	Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival. Molecular Cancer Research, 2013, 11, 901-911.	3.4	84
99	HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biology, 2013, 10, 1312-1323.	3.1	53
100	Failure Patterns in Resected Pancreas Adenocarcinoma. Annals of Surgery, 2013, 258, 331-335.	4.2	68
101	Biomarkers in Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 530-538.	2.0	101
102	HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. Cancer Biology and Therapy, 2012, 13, 946-955.	3 . 4	36
103	Is Resection Equivalent to Transplantation for Early Cirrhotic Patients with Hepatocellular Carcinoma? A Meta-Analysis. Journal of Gastrointestinal Surgery, 2012, 16, 1897-1909.	1.7	45
104	A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers. PLoS ONE, 2012, 7, e40157.	2.5	99
105	Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades. Annals of Surgical Oncology, 2012, 19, 169-175.	1.5	307
106	Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2012, 16, 753-761.	1.7	48
107	Sarcoid-Reaction Mimicking Metastatic Malignant Hepatopancreatobiliary Tumors: Report of Two Cases and Review of the Literature. Journal of Gastrointestinal Surgery, 2012, 16, 1245-1250.	1.7	14
108	Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 2011, 475, 106-109.	27.8	1,831

#	Article	IF	CITATIONS
109	Reexamining a proposal. Cancer Biology and Therapy, 2011, 12, 750-755.	3.4	11
110	Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study. Annals of Surgical Oncology, 2010, 17, 981-990.	1.5	237
111	Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis. Journal of Gastrointestinal Surgery, 2010, 14, 379-387.	1.7	183
112	Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research, 2009, 69, 3681-3688.	0.9	126
113	<i>SMAD4</i> Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 4674-4679.	7.0	335
114	Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence. Cancer Research, 2009, 69, 984-991.	0.9	26
115	Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiotherapy and Oncology, 2009, 92, 244-248.	0.6	50
116	Duodenojejunostomy Leaks After Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2008, 12, 263-269.	1.7	32
117	<i>SOS1</i> mutations are rare in human malignancies: Implications for Noonan syndrome patients. Genes Chromosomes and Cancer, 2008, 47, 253-259.	2.8	40
118	Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 412-418.	7.0	145
119	New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8. American Journal of Surgical Pathology, 2008, 32, 188-196.	3.7	121
120	Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biology and Therapy, 2007, 6, 324-328.	3.4	50
121	Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biology and Therapy, 2007, 6, 1569-1575.	3.4	63
122	Cholangiocarcinoma. Annals of Surgery, 2007, 245, 755-762.	4.2	1,120
123	Biochemical Markers Predict Morbidity and Mortality after Pancreaticoduodenectomy. Journal of the American College of Surgeons, 2007, 204, 1029-1036.	0.5	107
124	Retroperitoneal Paraganglioma: Single-Institution Experience and Review of the Literature. Journal of Gastrointestinal Surgery, 2006, 10, 1156-1163.	1.7	41
125	Assessment of Complications After Pancreatic Surgery. Annals of Surgery, 2006, 244, 931-939.	4.2	684
126	Periampullary and Pancreatic Incidentaloma. Annals of Surgery, 2006, 243, 673-683.	4.2	142

#	Article	IF	CITATIONS
127	Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations. Modern Pathology, 2006, 19, 1157-1163.	5.5	45
128	Hospital Readmission After Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2006, 10, 1243-1253.	1.7	106
129	Genetics and pathology of pancreatic cancer. Hpb, 2006, 8, 324-336.	0.3	36
130	Pancreaticoduodenectomy in the Very Elderly. Journal of Gastrointestinal Surgery, 2006, 10, 347-356.	1.7	203
131	Does Pancreatic Duct Stenting Decrease the Rate of Pancreatic Fistula Following Pancreaticoduodenectomy? Results of a Prospective Randomized Trial. Journal of Gastrointestinal Surgery, 2006, 10, 1280-1290.	1.7	284
132	1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution Experience. Journal of Gastrointestinal Surgery, 2006, 10, 1199-1211.	1.7	1,303
133	Multiple-criterion evaluation of reported mutations: A proposed scoring system for the intragenic somatic mutation literature. Cancer Biology and Therapy, 2006, 5, 360-370.	3.4	13
134	Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biology and Therapy, 2006, 5, 349-359.	3.4	21
135	Genomic Copy Number Changes Affecting the Thymidylate Synthase (TYMS) Gene in Cancer: A Model for Patient Classification to Aid Fluoropyrimidine Therapy. Cancer Research, 2006, 66, 9369-9373.	0.9	33
136	Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX. Carcinogenesis, 2005, 26, 1811-1820.	2.8	25
137	Gender affects macrophage cytokine and prostaglandin E2 production and PGE2 receptor expression after trauma1. Journal of Surgical Research, 2004, 122, 1-7.	1.6	21
138	Mutations in the protein kinase A R1 \hat{l} ± regulatory subunit cause familial cardiac myxomas and Carney complex. Journal of Clinical Investigation, 2001, 107, 235-235.	8.2	2
139	Mutations in the protein kinase A R1 \hat{l} ± regulatory subunit cause familial cardiac myxomas and Carney complex. Journal of Clinical Investigation, 2000, 106, R31-R38.	8.2	247